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Abstract
Glucocorticoids (GCs) selectively trigger cell death in the multiple myeloma cell line
MM1S which express NR3C1/Glucocorticoid Receptor (GR) protein, but fail to kill
MM1R cells which lack GR protein. Given recent demonstrations of altered
microRNA profiles in a diverse range of haematological malignancies and drug
resistance, we characterized GC inducible mRNA and microRNA transcription
profiles in GC sensitive MM1S as compared to GC resistant MM1R cells.
Transcriptome analysis revealed that GCs regulate expression of multiple genes
involved in cell cycle control, cell organization, cell death and immunological
disease in MM1S cells, which remain unaffected in MM1R cells. With respect to
microRNAs, mir-150-5p was identified as the most time persistent GC regulated
microRNA, out of 5 QPCR validated microRNAs (mir-26b, mir-125a-5p, mir-146-5p,
mir-150-5p, and mir-184), which are GC inducible in MM1S but not in MM1R cells.
Functional studies further revealed that ectopic transfection of a synthetic mir-150-
5p mimics GR dependent gene expression changes involved in cell death and cell
proliferation pathways. Remarkably, despite the gene expression changes
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observed, overexpression of mir-150-5p in absence of GCs did not trigger
significant cytotoxicity in MM1S or MM1R cells. This suggests the requirement of
additional steps in GC induced cell death, which can not be mimicked by mir-150-
5p overexpression alone. Interestingly, a combination of mir-150-5p transfection
with low doses GC in MM1S cells was found to sensitize therapy response,
whereas opposite effects could be observed with a mir-150-5p specific antagomir.
Although mir-150-5p overexpression did not substantially change GR expression
levels, it was found that mir-150-5p evokes GR specific effects through indirect
mRNA regulation of GR interacting transcription factors and hormone receptors,
GR chaperones, as well as various effectors of unfolded protein stress and
chemokine signalling. Altogether GC-inducible mir-150-5p adds another level of
regulation to GC specific therapeutic responses in multiple myeloma.
Introduction
Multiple myeloma (MM) is a B-cell neoplasm characterized by the accumulation
of clonal malignant plasma cells in the bone marrow and often correlated with
various cytogenetic abnormalities such as del(13), t(11:14), non-hyperdiploidy,
and del(17p) [1, 2]. The disease accounts for 10% of the haematological
malignancies and approximately 1% of cancer-related deaths in Western countries
[3]. Therapy against multiple myeloma consists of drugs which can decrease the
clonal plasma cell population. Initial treatment towards the disease depends
mainly on patients age and comorbidities. The ability of glucocorticoids (GCs) to
efficiently kill lymphoid cells has led to their inclusion in essentially all
chemotherapy protocols for lymphoid malignancies. For patients under the age of
65 high doses of chemotherapy of different combinations such as thalidomide–
dexamethasone-bortezomib based regimens, and lenalidomide–dexamethasone
followed by autologous haematopoietic stem cell transplantation has been a
practice in the clinic in the recent years [4, 5, 6, 7, 8]. Despite the progress in
therapy, MM remains largely incurable, due to low remission rates of
conventional therapies resulting in short survival times (3–4 years) and the
development of drug resistance. Numerous novel drug combinations are currently
being tested to prevent resistance and improve GC efficacy in the therapy of
lymphoid malignancies [9].
Glucocorticoids (GCs) are steroid hormones, which exert their pro- or anti-
apoptotic actions via the glucocorticoid receptor (GR, NR3C1) and alterations in
gene expression [10, 11]. The GRa isoform, which is the main mediator of GC
effects, comprises three main functional domains: an N-terminal domain (NTD),
a DNA binding domain (DBD) and a ligand binding domain (LBD) [12]. The
inactive form of GRa primarily resides in the cytoplasm forming a chaperone
complex with its binding partners such as heat shock proteins, FKBP51, FKBP52,
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CYP40 and other proteins [13]. Upon binding with the GC’s, the GR becomes
activated and translocates to the nucleus. The activated GR has several different
modes of action at the cellular level. The most prominent one is transactivation in
which the activated GR binds to a glucocorticoid-response element (GRE) and
induces gene expression. Further, GR can bind negative GRE sites (nGREs) or
tether bound transcription factors (NFkB, AP1, P53 or STAT) and hence
(trans)represses gene expression [14]. Although being known as a strong inducer
of apoptosis in lymphoid cells for almost a century, the signaling pathways
regulating the susceptibility or resistance of cancer cells to GCs are only partly
revealed. Besides slow genomic GC actions depending on nuclear gene regulation,
also rapid non-genomic effects of GCs in the cytoplasm modulate the apoptotic
response [15, 16]. With respect to development of GC therapy resistance, various
mechanisms have been proposed including GR degradation, Akt dependent GR
phosphorylation, reduced histone deacetylase-2 (HDAC2) activity, excessive
activation of the transcription factor NFkB or AP1, elevated macrophage
migration inhibitory factor, oxidative stress and P-glycoprotein mediated
regulation of drug efflux [17, 18, 19, 20]. A novel emerging hypothesis is that
microRNAs modulate GC therapy response via (post-transcriptional) regulation
of multiple mRNA targets involved in GR signaling related to cell proliferation
and cell death [21, 22, 23, 24]. MiRNAs are short non-coding RNAs of
approximately 22 nucleotides length which regulate expression of tens to
hundreds of genes via mRNA degradation or translational repression, based on
the sequence complementarity to the miRNA seed region (positions 2–8) at the
39UTR of the mRNA [25]. Alternatively, miRNAs may indirectly reprogram
transcriptional responses by changing mRNA levels of transcription factor levels
[26]. As such, microRNAs may represent a possible feedback mechanism to fine-
tune the magnitude of GC induced cell death via direct regulation of GR mRNA/
protein levels or indirect regulation of GR interaction partners or downstream
GC/GR responsive target mRNAs. Since miRNA dysregulation has a profound
impact on cell differentiation, development, apoptosis and cell cycle progression,
their expression profiles can be used as biomarkers for cancer type and grade
(prognosis) and/or personalized therapy response [27]. To characterize the
regulatory role of GC inducible microRNAs in multiple myeloma therapy
response, we have compared mRNA and microRNA transcription profiles in GC
sensitive MM1S cells and GC resistant MM1R cells upon exposure to GC. The
latter cell model is frequently used for elucidation of regulatory mechanisms
involved in GC therapy resistance in MM cells [28].
Materials and Methods
Cell Culture and cell viability
GC sensitive MM1S (CRL-2974) and GC resistant MM1R cell lines (CRL-2975)
have been previously described [28] and were purchased from ATCC. Briefly,
MM1S cells are a B-lymphoblast myeloma cell line derived from a 42 years old
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black female. The MM1R cell line is a steroid resistant subclone derived from
MM1S cells, chronically exposed to dexamethasone (Dex). Cells were cultivated in
RPMI-1640 Medium supplied with 10% Fetal Bovine Serum (E.U Approved;
South American Origin) and 0.5% Penicillin/Streptomycin Solution (Invitrogen).
The cell lines were additionally supplemented with 1% MEM Non-Essential
Amino Acids and 1% Sodium Pyruvate (Invitrogen). Each cell line was
maintained at 37 C˚ in the atmosphere of 5% CO2 and 95% air, 95–98% humidity,
until confluence. Cell viability was assessed by using colorimetric assay with 3-(4,
5-dimethylthiozol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (Sigma
Aldrich, St. Louis, MO, United States of America) as previously described [29].
Antibodies and reagents
Water soluble dexamethasone was purchased from (Sigma Aldrich, St. Louis, MO,
United States of America) and 10 mM stock solutions were prepared in sterile
water. Anti-GRa (sc-8992) antibody, anti-PARP antibody (sc-7150) were
purchased from Santa Cruz Biotechnology (Dallas, United States of America), and
anti-a-tubulin (T5168) was purchased from Sigma Aldrich (St. Louis, MO, US).
RNA extraction and microarray processing
Total RNA from MM1S and MM1R cells, either Dex treated (1 mM) or
transfected with mock or mir-150-5p mimetics, from three independent
experiments was isolated using RNeasy Mini Kit (Qiagen, Venlo, Netherlands)
according to the manufacturer’s protocol. Following extraction and concentration
measurement (NanoDrop 1000, Thermo Scientific, Waltham, MA, USA) total
RNA was quality controlled on a Bio-Rad Experion (Bio-Rad, Hercules, CA,
USA). 500 ng of total RNA was amplified using the Illumina Total Prep RNA
Amplification kit (Life Technologies, Carlsbad, CA, USA). Briefly, RNA was
reverse transcribed using T7 oligo(dT) primers, after which biotinylated cRNA
was synthesized through an in vitro transcription reaction. 750 ng of amplified
cRNA was hybridized to a corresponding array of a HumanHT12 beadchip
(Illumina, San Diego, CA, USA). Multiplicates were performed. The beadchip was
incubated for 18 hours at 58 C˚ in a hybridization oven under continuous rocking.
After several consecutive washing steps (see manufacturer’s protocol), bead
intensities were read on an Illumina Iscan.
Microarray data analysis
All the raw data intensities generated were read using the ‘‘beadarray’’ package
(v2.8.1) in R [30]. Intensities were quantile normalized and differential gene
expression between samples was estimated using ‘‘Limma’’ (v3.14.1). Resulting p-
values were corrected for multiple hypothesis testing using the Benjamini-
Hochberg method. Next to estimating gene expressions, euclidean distances
between samples and genes were calculated and used as a distance metric in a
hierarchical cluster analysis with MeV [31]. Pathway analysis was performed in
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the Ingenuity Pathway Knowledge Base (Ingenuity Systems, Redwood City, CA,
USA) according to the instructions provided. A fold change cut-off of 2 as well as
false discovery rate of 0.1% were set to identify genes whose expression was
significantly differentially regulated. Raw array data were uploaded to the Gene
Expression Omnibus (GEO) database and have accession number GSE59805.
cDNA conversion and QPCR analysis
Briefly 1 mg of RNA was converted into cDNA using Go Script reverse
transcription system according to manufacturer’s instructions (Promega,
Madison, WI, United States of America). Sybr green was purchased from (Bioline,
London, UK). QPCR was performed using ABI7300 system (Applied biosystems,
Life Technologies Corporation).
miRNA analysis
miRNA isolation was performed with a miRNeasy kit (Qiagen, Venlo,
Netherlands) according to manufacturer instructions. Stem-loop RT-qPCR
miRNA expression profiling of 760 microRNAs was done as previously described
[32, 33]. Raw expression values were normalized using the global mean
normalization strategy [32]. Validation of QPCR array results was done by reverse
transcription of total RNA containing miRNA and miRNA detection by real-time
PCR, using respectively miScript II RT Kit and miScript SYBR Green PCR Kit
(Qiagen, Venlo, Netherlands). MicroRNA specific QPCR primer sets against
human mir-146a (MS00003535), mir-491-5p (MS00031899), mir-146b-5p
(MS00003542), mir-26b-5p (MS00003234), mir-150-5p (MS00003577), mir-330-
3p (MS00031738), mir-195 (MS00003703), mir-184(MS00003640), mir-125a-5p
(MS00003423) were purchased from Qiagen (Venlo, Netherlands). For
microRNA target and pathway prediction, miRWalk software was applied [34].
Correlation of mRNA and microRNA transcription profiles of MM1S and MM1R
cells either non-treated or treated with Dex, or following mock transfection or
transfection with mir-150-5p mimetic was performed with IPA software.
In vitro transfection of MM cells with synthetic miR-150-5p mimetic
and antagomir
Mir-150-5p mimetic and antagomir were purchased from Qiagen (Venlo,
Netherlands). A total of 56106 cells was electroporated with mock control or
synthetic mir-150-5p at a final concentration of 150 nmol/L, with Nucleofector
Kit V, using AMAXA Transfection System, program O23 from (LONZA, Basel,
Switzerland) as described elsewhere [35].
Protein isolation
56106 cells were seeded in 10 cm dishes and protein lysates of different
experimental setups were prepared for Western analysis with 1XSDS Sample
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buffer containing 62.5 mM Tris-HCL pH-6.8, 2% SDS, 10% Glycerol, 0.5%
Bromophenol Blue, DTT (5 mM).
Statistical Analysis
Statistics were performed using one way ANOVA, two way ANOVA followed by
Dunnett’s and Bonferroni post-test and one-tailed paired student t-test using
graph pad prism5 software.
Results
Dexamethasone decreases cell viability in a dose and time
dependent manner in GC sensitive MM1S but not GC resistant
MM1R cells
Before investigation of the regulatory role of GC inducible microRNA in NR3C1/
GR responsive gene expression and cell death responses, we first characterized the
GC therapy response in MM1S and MM1R cells. Briefly, MM1S and MM1R cells
were left untreated or treated with 1 mM of the synthetic GC agonist
dexamethasone (Dex) for respectively 6 h, 24 h, 48 h, 72 h. mRNA and proteins
were isolated at each time point and analysed for corresponding NR3C1/GRa
expression. Treating the cells with different concentrations of Dex for 24 h, 48 h
and 72 h followed by measuring cell viability by a MTT colorimetric assay,
revealed a dose and time dependent decrease in cell survival of MM1S cells upon
GC exposure (Fig. 1A & 1B). In contrast Dex lacks the capacity to induce
cytotoxicity in MM1R cells and rather triggers a weak growth stimulatory effect
[28, 35, 36, 37]. In line with the different GC response in both cell lines, QPCR
analysis demonstrates significant NR3C1/GRa mRNA transcription in MM1S, but
near background levels of NR3C1/GRa mRNA in MM1R cells (Fig. 1C). Western
analysis finally confirms significant levels of GRa protein expression in MM1S and
undetectable levels of GRa protein in MM1R cells (Fig. 1D–E). As can be observed
from Fig. 1D, MM1S cells express multiple translational isoforms of GRa [38, 39],
of which expression decreases following GC treatment.
Despite the time dependent reduction of GR mRNA and protein levels upon
24–72 h GC treatment (Fig. 1C–1D), the cell death response in MM1S is not
abrogated. Furthermore, GC induced cell death triggers time dependent cleavage
of the apoptotic marker PARP in MM1S but not in MM1R cells (Fig. 1D–E). In
contrast to GR levels observed in MM1S, expression levels of most GR isoforms in
MM1R are below detection limit, although background levels of a 70 kDa variant
can still be detected upon prolonged exposure (data not shown). Remarkably,
although Dex completely lacks capacity to induce cytotoxicity in MM1R cells, a
weak growth stimulatory effect can be observed upon prolonged exposure of GC
in MM1R cells. This maybe attributed to residual activity of a possible anti-
apoptotic translational isoform of GR [38].
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Dexamethasone triggers GC specific transcriptional changes in
cell cycle, DNA damage/repair, cell death and immunological
pathways in MM1S but not MM1R
To evaluate specific gene expression changes linked to GC therapy response in
multiple myeloma, mRNA was isolated from three independent experiments from
MM1S and MM1R cells exposed for 72 h to the GC Dex (1 mM). After mRNA
isolation, genome-wide transcription profiles were determined by Illumina array
hybridisation. Results were analysed with the R-package ‘‘Limma’’ (v3.14.1)
[40, 41], which resulted in the identification of 268 downregulated and 151
upregulated genes in MM1S, after filtering for a minimal two-fold transcriptional
change in Dex treated samples versus control setup (absolute fold change .2) and
adjusted P-value ,0.05 (Gene Expression Omnibus (GEO) database GSE59805).
In MM1R, no significant Dex responsive changes could be detected, in line with
the GC resistant phenotype and the absence of GRa in MM1R cells (see Fig. 1).
Figure 1. Dexamethasone decreases cell viability in a dose and time dependent manner in GC sensitive MM1S but not GC resistant MM1R cells.
(A–B) dose response curves of MM1S and MM1R cells treated with dexamethasone at different concentrations for 24, 48 and 72 h as determined by MTT
colorimetric assay. Data represent (mean¡ SEM) values of three independent experiments. (C) time dependent changes in GRa mRNA levels upon 1 mM
dexamethasone treatment. Data represent (mean¡ SEM) values of three independent experiments normalized to 28sRNA housekeeping gene and relative
to MM1S untreated condition (S UT). Means with ***, **, * are significantly different (p,0.001, ,0.01 or ,0.05 and ns are not significantly different as
determined by one-way ANOVA (Dunnett’s Post-test) (D) Time dependent changes in GRa protein levels and PARP cleavage in MM1S and MM1R cells
following treatment of 1 mMDex. (E) Densitometric analysis of western blot signals (n52) of protein levels of GR (92 kDa), b-Actin (40 kDa), full length PARP
(116 kDa) and cleaved PARP (89 kDa) in MM1S and MM1R, following treatment of 1 mM Dex. Significant differences between western signals in MM1R and
MM1S are indicated.
doi:10.1371/journal.pone.0113842.g001
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The heatmap (Fig. 2A) represents a graphical presentation of Dex specific
transcriptional changes in MM1S and lack of Dex response in MM1R cells in three
biological replicates, revealing highly reproducible and robust patterns of gene
expression. By QPCR analysis, we confirmed GC dependent transactivation of
GILZ (TSC22D3) target gene as well as GC specific (trans)repression of CDK2 in
MM1S but not in MM1R, in line with the Illumina array data and previous
reports [37, 42, 43, 44] (Fig. 2B). Remarkably, prolonged GC exposure (72 h) of
MM1R cells reveals weakly increased levels of CDK2 according to QPCR analysis,
which could not be detected by less sensitive microarray analysis. This effect may
be attributed to residual activity of anti-apoptotic GR isoforms in MM1R, which
may also contribute to weak growth stimulatory effects (Fig. 1A) upon prolonged
exposure [38]. Integrated pathway analysis (IPA) further revealed that GCs trigger
gene expression changes which promote cell death, decrease cell proliferation (cell
cycle, DNA replication) and regulate immunological haematological pathways in
MM1S but not MM1R (Table 1), in line with the reduced cell viability assay in
MM1S (see Fig. 1). Next, we further validated microarray results of some
Figure 2. Dexamethasone triggers GC specific transcriptional changes in cell cycle, DNA damage/repair, cell death and immunological pathways
in MM1S but not MM1R. (A) The heat map represents relative gene expression levels of MM1S and MM1R cells, left untreated (solvent) or treated with
1 mM Dex for 72 h. Gene expression changes .2-fold and with a p-value ,0.05 are plotted on the heat map. (B) Left panel: Realtime quantitative PCR
(QPCR) validation of Dex dependent activation of GILZ (TSC22D3) mRNA transcription Right panel: Realtime quantitative PCR (QPCR) validation of Dex
dependent repression of CDK2 mRNA in MM1S but not in MM1R. Means with ***, **, * are significantly different (p,0.001, ,0.01 or ,0.05 respectively) as
compared to control setups, determined by one-way (Dunnett’s Post-test) (C–D) Realtime quantitative PCR (QPCR) validation and Illumina microarray
observation of the top GC regulated genes involved cell cycle, DNA damage/repair and cell death in S5MM1S but not R5MM1R. All the QPCR validation
studies have been normalized to the 28S RNA housekeeping gene and are represented relative to MM1S untreated condition (S UT). Bar graphs represent
relative mRNA (mean ¡ SEM) levels of three independent experiments. Means with ***, **, * are significantly different (p,0.001, ,0.01 or ,0.05
respectively) from control setups as determined by two-way ANOVA (Bonferroni post-tests).
doi:10.1371/journal.pone.0113842.g002
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additional target genes involved in cell cycle, DNA damage/repair and cell death.
As can be observed from (Fig. 2C & 2D), the QPCR validation results correlate
with the obtained microarray data. Furthermore, by analyzing patterns of
coregulated genes, IPA software allows to identify activation or inhibition of
possible upstream regulators (kinases, receptors, transcription factors) involved in
gene expression changes [45]. The latter analysis predicts highly significant
activation of Dex liganded NR3C1 and TP53 transcription factors, in regulating
MM1S cell cycle arrest and/or apoptosis [46] (Table 2). Furthermore, predicted
activation of IKK and cyclin dependent kinases CDKN2A, CDKN1A may be
indicators of DNA damage/cell death and cell cycle events triggered by Dex
[47, 48, 49, 50]. Finally, possible inhibition of anti-apoptotic prosurvival signals
stimulated by TNF and AKT kinases may also contribute to Dex induced cell
death in MM1S (Table 2).
MicroRNAs responsive to GC in MM1S cells, but unresponsive to
GC in MM1R cells, are predicted to modulate cell cycle, cell
growth and proliferation pathways
Total RNA was isolated from MM1S and MM1R cells treated with 1 mM Dex for
72 h, qPCR profiling of 760 miRNAs as previously described [32]. This allowed to
identify 30 GC inducible and 14 GC repressed miRNAs (.2-fold) in MM1S,
which do not change transcription in MM1R cells (summarized in Table 3). Next,
IPA analysis was applied to cross compare microRNA and mRNA profiles in
MM1S to predict target genes and top pathways which are affected by microRNA
expression. Venn diagram analysis of the top 5 ranked molecular and cellular
pathways enriched for genes differentially expressed in MM1S upon Dex exposure
Table 1. Top molecular and cellular biofunctions upon 1 mM Dex treatment in MM1S cells for 72 h.
Cellular function P-value
Predicted Activating
state Z-score
Cell Death and Survival 1.03E-12 Increased 3.301
Cellular Assembly and Organization,
DNA Replication, Recombination, Repair
1.98E-09 Decreased 22.711
Cell Cycle 9.63E-09 Decreased 22.043
DNA Replication, Recombination, and Repair 2.89E-07 Decreased 22.22
Cellular Assembly and Organization,
DNA Replication, Recombination, Repair
9.74E-07 Decreased 22.138
Cellular Development, Cellular
Growth and Proliferation
1.28E-06 Decreased 23.067
Cellular Growth and Proliferation 1.81E-06 Decreased 23.185
Cell Cycle 5.96E-06 Decreased 22.205
Cell Cycle 7.98E-06 Decreased 22.305
Cancer, Hematological Disease,
Immunological Disease
1.04E-05
Immunological Disease 2.27E-05
doi:10.1371/journal.pone.0113842.t001
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and predicted microRNA target genes responsive to Dex treatment reveals that
GC responsive microRNAs may target mRNAs involved in cell cycle and cell
proliferation pathways (Fig. 3A). For example, Dex inducible microRNAs mir-
150-5p, mir-152, mir-146b-5p, mir-1290, mir-125a-5p, mir-1206 are predicted to
modulate multiple target genes involved in cell cycle, cellular growth and
proliferation pathways (as yellow marked in Table S1).
To reduce the number of Dex responsive microRNA for further validation and
functional studies, we next cross compared the list of GC responsive miRNA
identified in MM1S with a list of miRNAs predicted to regulate the GR(NR3C1)
pathway (Biocarta) according to the MiRWalk database [34] (Fig. 3B). This
generated a shortlist of 11 miRNAs, which were selected for further QPCR
validation. Along the same line, IPA correlation of Dex repressed mRNAs and 30
Dex inducible miRNAs identified a similar GR specific role for mir-150-5p, mir-
146b-5p and mir-125a-5p in the cell cycle and cellular growth and proliferation
pathway (Table S1). Time dependent GC responsive changes in transcription
levels of 11 selected microRNAs were evaluated by QPCR in MM1S and MM1R
cells exposed for different time points (6 h, 24 h, 48 h and 72 h) to 1 mM of Dex.
QPCR analysis could confirm time and GC specific induction of 5 hsa-
microRNAs i.e. of mir-26b, mir-125a-5p, mir-146-5p, mir-150-5p, and mir-184 (
Fig. 3C). Finally, hsa-mir-150-5p was selected for further functional studies
because of its persistent GC responsive transcription between 6 and 72 h, and GC
dose dependent regulation of mir-150-5p following 72 h treatment (Fig. 3D).
Upon cross comparing 1203 Dex responsive target genes from MM1S cells with
1 mM Dex treatment for 72 h (gene selection was done based on p-value ,0.05
and absolute fold change .1.5) and 3626 predicted hsa-mir-150-5p targets via the
miRWalk database (prediction by at least 4 out of 10 available algorithms, i.e.
DIANAmT, miRanda, miRDB, miRWalk, RNAhybrid, PICTAR4, PICTAR5,
PITA, RNA22 and Targetscan), 196 common mRNA/gene targets (Fig. 4A) were
identified in MM1S, which remain unaffected in MM1R cells (detailed list of
genes can be found in Table S2). Upon employing IPA analysis, the 196 mRNA
predicted GC responsive mir-150-5p target genes are enriched for cell death, cell
Table 2. Top upstream regulators upon 1 mM Dex treatment in MM1S cells for 72 h.
Upstream
regulator Molecule type P-value
Predicted activation
state Activation Z-score
TP53 Transcription regulator 1.53E-49 Activated 5.504
CDKN1A Kinase 5.31E-47 Activated 4.322
CDKN2A Transcription Regulator 1.80E-37 Activated 6.844
Dexamethasone Chemical drug 1.14E-11 Activated 2.719
NR3C1 Ligand-dependent nuclear receptor 4.58E-08 Activated 2.359
I kappa b kinase Complex 4.09E-07 Activated 2.629
PPARG ligand-dependent nuclear receptor 1.35E-05 Inhibited 22.804
doi:10.1371/journal.pone.0113842.t002
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morphology, cell cycle, cellular growth and proliferation pathways (Fig. 4A). Of
special note, IPA upstream analysis predicts that mir-150-5p gene target genes are
responsive for regulation by GC (Dex)/NR3C1, PPAR or STAT/IFNc signaling (
Fig. 4B).
Transfection of a mir-150-5p mimetic triggers GR specific gene
expression in MM1S but not in MM1R cells, without modulating GR
protein levels
To validate possible mir-150-5p effects on the predicted mRNA targets and/or cell
cycle or cell proliferation pathways, we performed transfection experiments in
MM1S and MM1R cells with a synthetic mir-150-5p mimetic in comparison to
Table 3. Dex regulated miRNAs in MM1S but not MM1R upon 1 mM Dex treatment for 72 h.
hsa-miR Fold activation Log2FC hsa-miR Fold repression Log2FC
hsa-miR-146a 2.10E+00 1.4 hsa-miR-492 3.62E+08 0.00
hsa-miR-152 2.17E+00 1.5 hsa-miR-1275 4.13E+04 0.00
hsa-miR-491-5p 2.18E+00 1.5 hsa-miR-766 3.14E+04 0.01
hsa-miR-28-5p 2.20E+00 1.5 hsa-miR-412 6.25E+03 0.01
hsa-miR-590-5p 2.20E+00 1.5 hsa-miR-636 3.81E+03 0.02
hsa-miR-454# 2.23E+00 1.5 hsa-miR-181c 3.34E+03 0.02
hsa-miR-146b-5p 2.24E+00 1.5 rno-miR-29c# 2.70E+03 0.02
hsa-miR-627 2.43E+00 1.6 hsa-miR-603 1.91E+03 0.02
hsa-miR-26b 2.58E+00 1.6 hsa-miR-100# 1.64E+03 0.02
hsa-miR-95 2.69E+00 1.6 hsa-miR-17# 3.71E+02 0.05
hsa-miR-324-3p 3.16E+00 1.8 hsa-miR-106b# 1.03E+01 0.31
hsa-miR-150-5p 3.54E+00 1.9 hsa-miR-27b 5.46E+00 0.43
hsa-miR-484 3.91E+00 2.0 hsa-miR-92a-1# 4.61E+00 0.47
hsa-miR-1290 4.07E+00 2.0 hsa-miR-301b 2.11E+00 0.69
hsa-miR-652 4.09E+00 2.0
hsa-miR-330-3p 4.19E+00 2.0
hsa-miR-195 4.62E+00 2.1
hsa-miR-184 8.25E+00 2.9
hsa-miR-125a-5p 2.49E+02 15.8
hsa-miR-126 2.67E+02 16.4
hsa-miR-515-3p 3.28E+02 18.1
hsa-miR-623 4.98E+02 22.3
hsa-miR-1206 8.74E+02 29.6
hsa-miR-802 1.01E+03 31.7
hsa-miR-451 1.11E+03 33.4
hsa-miR-892b 4.12E+03 64.2
hsa-miR-629 4.78E+03 69.1
hsa-miR-518b 7.14E+03 84.5
hsa-miR-663B 4.05E+04 201.3
hsa-miR-34B 5.69E+05 754.2
doi:10.1371/journal.pone.0113842.t003
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Figure 3. Experimental validation of GC inducible microRNAs, potentially involved in regulation of the NR3C1(GR) pathway in MM1S cells (A)
Venn-diagram which summarizes the overlap between the top 5 predicted molecular and cellular functions generated by IPA from GC regulated miRNAs and
GC regulated mRNAs (B) Venn-diagram which represents the crosscomparison of the list of GC responsive miRNAs identified in MM1S with the list of
GR(NR3C1) pathway specific miRNAs according to MiRWalk prediction freeware. (C) Real-time QPCR validation of the transcription levels of 9 common
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Dex treatment. Remarkably, although MM1S and MM1R show similar
transcription levels of mir-150-5p upon mimetic transfection (Fig. 5A), we could
only observe significant changes in mir-150-5p responsive mRNAs in MM1S but
not in MM1R cells, upon analysing Illumina mRNA profiles. Interestingly, upon
cross comparing Dex treated and mir-150-5p mimetic transfected MM1S/MM1R
cells, IPA analysis revealed a remarkable overlap in mRNAs affected related to cell
cycle-proliferation, DNA repair and cell death pathways in MM1S, as well as lack
of effects for both setups in MM1R cells (Fig. 5B) (Table 4 and 5). To evaluate
miRNAs selected in Fig. 3B, in MM1S and MM1R cells treated for 24, 48 or 72 h with 1 mM Dex. (D) GC dose responsive regulation of mir-150-5p levels in
MM1S cells treated for 72 h with GC. All the miRNA QPCR validation studies have been normalized to SNORD 95 and SNORD 96A housekeeping miRNAs
according to manufacturer instructions and relative to MM1S untreated condition (S UT). Bar graphs represent relative miRNA (mean¡ SEM) levels of three
independent experiments as compared to control setups. Means with ***, **, * are significantly different to control setups (p,0.001, ,0.01 or ,0.05) as
determined by one-way ANOVA (Dunnetts Post test).
doi:10.1371/journal.pone.0113842.g003
Figure 4. Predicted role for mir-150-5p in regulation of cell death and survival, cell cycle, cellular growth and proliferation in MM1S cells. (A) Venn-
diagram which represents the crosscomparison of 3626 predicted hsa-mir-150-5p targets according to miRWalk software and 1203 dexamethasone
responsive target genes in MM1S cells, which remain unaffected in MM1R cells (B) IPA upstream analysis of the predicted microRNA target mRNAs in
MM1S cells.
doi:10.1371/journal.pone.0113842.g004
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Figure 5. Mir-150-5p mimetic transfection triggers GR specific gene expression in MM1S but not in MM1R cells, without modulating GR protein
levels. (A) QPCR based quantification of synthetic mir-150-5p levels present 72 h after transfection of MM1S and MM1R cells. The miRNA expression
levels have been normalized to SNORD 95 and SNORD 96A housekeeping miRNAs and are presented relative to MOCK control. Bar graphs represent
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whether mir-150-5p may change GR/NR3C1 mRNA levels or protein stability, we
performed QPCR and Western blot analysis following mir-150-5p transfection in
MM1S cells. From Fig. 5C and D, it can be observed that mir-150-5p transfection
does not change GR/NR3C1 mRNA or protein levels respectively. These results
are in line with the in silico data, showing that none of the validated GC-inducible
miRs are targeting GR-39UTR mRNA (Fig. 5E and Table S3). Altogether, these
results suggest that the mir-150-5p may mediate indirect GR like effects.
The genes involved in cell cycle-proliferation, DNA repair and cell death
pathways which are regulated in Dex treated and mir-150-5p mimetic transfected
MM1S/MM1R cells are indicated in Figure 6A and 6B or summarized in Table S4.
To further characterize crosstalk between GC treatment and mir-150-5p
transfection, we also performed microarray analysis of combination setups of mir-
150-5p with 1 nM Dex, since 1 mM Dex treatment combinations did not yield
array quality RNA because of excessive cytotoxicity. As can be noted from Fig. 6A
and 6B, 1 nM Dex treatment triggers weaker gene expression changes as compared
to 1 mM Dex treatment. Furthermore, since mir-150-5p levels upon transfection
increase 30-fold (Fig. 6A) as compared to 3-fold induction upon Dex treatment (
Fig. 3D), mir-150-5p mimetic overexpression triggers stronger gene expression
changes than 1 nM Dex treatment. As such, combining mir-150-5p transfection
with 1 nM Dex treatment did not further increase gene expression changes elicited
by mir-150-p transfection alone (Fig. 7A & B). A further detailed comparison of
GC and mir-150-5p responsive activation (i.e. GILZ and FKBP5) (Fig. 7A) or
relative miRNA (mean ¡ SEM) levels of three independent experiments. Means with ***, **, * are significantly different (p,0.001, ,0.01 or ,0.05) from
control setups according to two-way ANOVA (Bonferroni post-tests). (B) Comparison of top enriched pathways (IPA) of mRNA changes in MM1S cells
treated for 72 h to 1 mM Dex versus changes in MM1S and MM1R cells after 72 h mock transfection of transfection with synthetic mir-150-5p. (C) NR3C1/
GRa protein levels detected following 72 h transfection of a synthetic mir-150-5p mimetic in MM1S cells. (D) Venn-diagram which represents the overlap of
experimentally validated GC inducible microRNAs in MM1S cells with the list of miRNAs predicted to target the 39UTR of NR3C1. (E) QPCR analysis of
NR3C1/GRa mRNA levels present in MM1S cells following 72 h transfection of a synthetic mir-150-5p mimetic (left panel) or following 72 h Dex (1 mM)
treatment (right panel).
doi:10.1371/journal.pone.0113842.g005
Table 4. Top molecular and cellular functions regulated upon synthetic mir-150-5p transfection in MM1S cells.
Category p-Value
Predicted
Activation State Activation z-score
Cell Cycle 3.11E-06 Decreased –2.232
Cellular Growth and Proliferation 7.90E-05 Decreased –2.94
Cellular Assembly and Organization 2.45E-04 Decreased –2
DNA Replication, Recombination,
and Repair
2.45E-04 Decreased –2
Cellular Movement 9.24E-03 Decreased –2.201
Cell-To-Cell Signaling and Interaction 9.24E-03 Decreased –2.201
Immune Cell Trafficking 9.24E-03 Decreased –2.201
Inflammatory Response 9.24E-03 Decreased –2.201
doi:10.1371/journal.pone.0113842.t004
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repression (IL23A, SKP2, BUB, SREBF1) (Fig. 7B) of typical GR target genes
revealed similar effects in MM1S but lack of effects in MM1R. For example,
transactivation of the FKBP5 and GILZ genes can be observed following mir-150-
5p transfection and GC treatment in MM1S cells, although mir-150-5p effects on
FKBP5 expression are stronger. Along the same line, repression of GR target genes
IL23A, SKP2, BUB or SREBF1 can be observed upon Dex treatment as well
following mir-150-5p transfection. Finally, besides the common regulated genes,
additional GR target genes could be identified which were more selectively
affected by mir-150-5p transfection (SCNN1G) or else GC treatment (GILZ,
DUSP1, SGK1) indicating sophisticated fine tuning of GR regulation (Fig. 7C).
The GR-like gene response triggered by mir150-5p transfection is
associated with complex regulation of transcription factors, hsp
chaperones, kinases, cell cycle proteins, unfolded protein stress
(UPR), AMPK/mTOR and chemokine specific signalling networks
Due to lack of direct mir-150-5p effects on GR(NR3C1) mRNA and protein levels,
we assumed that GR like downstream effects may be caused by mir-150-5p
regulation of possible GR interaction partners (transcription factors, chaperones)
or alternative nuclear hormone receptors (Fig. 8A–B). Although mir-150-5p and
Dex setups both decrease MYB and ATF3 mRNA levels, opposite responses were
observed for FOS transcription factors. Of particular interest, MYB is a key
regulator of GR dependent gene expression in leukemia [51, 52, 53, 54, 55, 56, 57] (
Fig. 8A).
With respect to hormone receptors, most hormone receptors remained
constant upon mir-150-5p transfection (Fig. 8B), although weakly decreased levels
of NR3C2 (MR) could be detected in the setup with mir-150-5p, whereas NR3C2
levels remain stable in presence of Dex. Interestingly, as a consequence of
reciprocal crosstalk of NR3C2(MR) and NR3C1(GR) actions, suppressing MR
function may indeed result in ligand independent stimulation of GR actions [58].
Next, we evaluated changes in transcription levels of hormone receptor chaperone
Table 5. Top upstream regulators in mir-150-5p transfected MM1S cells.
Upstream
Regulator
Fold
Change
Molecule
Type
Predicted
Activation State Activation z-score
p-value of
overlap
TP53 1.156 transcription regulator Activated 2.056 9.11E-23
CDKN1A –1.86 kinase Activated 2.433 1.91E-13
IL6 –1.027 cytokine Inhibited –2.407 3.40E-13
CDKN2A 1.08 transcription regulator Activated 2.656 1.44E-09
dexamethasone chemical drug Activated 2.668 3.35E-09
NR3C1 –1.218 ligand-dependent nuclear receptor Activated 2.007 1.07E-05
PPARG 1.04 ligand-dependent nuclear receptor Inhibited –3.153 5.40E-05
NFkB (complex) complex Inhibited –2.669 3.71E-03
doi:10.1371/journal.pone.0113842.t005
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molecules upon presence of mir-150-5p. Although most HSP mRNAs remain
unaffected, significant changes in HSPA8 and HSP90AB1 levels could be detected
following mir-150-5p transfection but not with Dex treatment, which may further
contribute in fine tuning basal activity of nuclear hormone receptors (Fig. 8C)
[59, 60, 61]. Furthermore mir-150-5p selectively decreases transcript levels of
ATF4, JUN, NFE2L1(NRF1), CEBP/B and IRF4 but not of NFE2L2, TP53 and
RelA (Fig. 8A).
Finally, we also explored possible upstream effects of mir-150-5p on receptor
kinase signalling pathways. Ligand independent hormone receptor (in)activation
via kinases, chemokines and cytokines is well documented nowadays
[62, 63, 64, 65, 66]. With respect to chemokine signalling, mir-150-5p transfection
and GC treatment were found to increase mRNA levels of CXCR4 and CX3CR1
and decrease levels of CXCR3, CCL3, CCL5 whereas other members remain
unaffected (Fig. 9A). Interestingly, various reports demonstrate a positive role for
CXCR4/CXCL12 in hormone independent receptor activation [65, 66, 67, 68, 69].
Surprisingly, we observed a significant increase in CXCR4 levels, upon mir-150-5p
transfection, in contrast to earlier reports demonstrating CXCR4 mRNA silencing
of its 39 UTR via mir-150-5p [68, 70]. Although various studies illustrate tumor
promoting and prometastatic effects of CXCR4 [71, 72], its expression also plays a
pivotal role in haematopoiesis [73] and has recently been reported as a good
prognostic indicator in multiple myeloma [74]. Finally, we also identified
remarkable effects on effectors in cell cycle (CDKN1A) and UPR/mTOR signalling
pathways (DDIT3, DDIT4, TXNIP) and the Tribble family Ser/Thr pseudokinase
(TRIB3) [75] which altogether may crosstalk with glucocorticoid receptor
signalling and GC therapy response in MM cells [76, 77, 78] (Fig. 9B). Of special
note, involvement of C/EBP and ATF4 (Fig. 8A) has been demonstrated in
transcriptional regulation of UPR stress proteins DDIT3, DDIT4, TXNIP [79, 80],
further corroborating our results.
Weak sensitisation of low dose GC therapy response by
mir-150-5p mimetic transfection can be reversed by transfection of
a mir-150-5p-specific antagomir in MM1S cells
Since mir-150-5p modulates various genes related to cell cycle, cell proliferation
and cell death pathways, we next wanted to measure cell death induced by ectopic
mir-150-5p transfection. Surprisingly, no substantial induction of cell death could
be observed by MTT-assay at 24, 48 and 72 h following transfection of MM1S cells
by increasing amounts of mir150-5p (Fig. 10A). The latter suggests that mir-150-
Figure 6. Mir-150-5p specific mRNA changes in MM1S are associated with pathways related to cell death and survival, cell cycle, cellular growth
and proliferation (A–B) mir-150-5p specific mRNA regulation of the genes involved in (i) cell cycle, (ii) cellular assembly and organization, (iii) DNA
replication, recombination and repair, (iv) cell growth and proliferation, (v) cell death and survival. Illumina BeadChip Gene Expression Array results are
presented as bar graphs, reflecting mean of gene expression fold change from three independent experiments of MM1S cells, treated for 72 h with 1 mMDex
vs control cells (upper panels A–B), or else of MM1S cells transfected for 72 h with synthetic mir-150-5p versus mock transfection, treated for 72 h with 1 nM
Dex or a combination thereof versus control samples (lower panels A–B).
doi:10.1371/journal.pone.0113842.g006
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Figure 7. Mir-150-5p transfection mimics GR like gene activation and repression response in MM1S and lack of response in MM1R cells. (A)
Realtime quantitative PCR (QPCR) validation of GILZ (TSC22D3) and FKBP5 mRNA induction in MM1S and in MM1R cells, following 72 h treatment with 1
nM or 1 mM Dex (left panel), or following 72 h transfection with synthetic mir-150-5p, 72 h treatment with 1 nM Dex, or a combination thereof (right panel).
Data represent (mean ¡ SEM) values of three independent experiments normalized to 28S RNA housekeeping gene and relative to the respective
untreated/solvent (UT) or MOCK control setups. Means with ***, **, * are significantly different (p,0.001, ,0.01 or ,0.05) from control setup as determined
by two-way ANOVA (Bonferroni posttest). (B) Realtime quantitative PCR (QPCR) validation of MYB, IL23A, SKP2, BUB1, SREBF1 mRNA repression levels
in MM1S or MM1R cells, following 72 h treatment with 1 nM or 1 mM Dex, or following 72 h transfection with synthetic mir-150-5p, 72 h treatment with 1 nM
Dex, or a combination thereof. Data represent (mean ¡ SEM) values of three independent experiments normalized to 28S RNA housekeeping gene and
relative to the respective untreated/solvent (UT) or MOCK control setups. Means with ***, **, * are significantly different (p,0.001, ,0.01 or ,0.05) from
control setup as determined by two-way ANOVA (Bonferroni posttests) (C) Illumina BeadChip Gene Expression Array results of selected genes are
presented as bargraphs, reflecting mean of gene expression fold change from three independent experiments of MM1S cells, treated for 72 h with 1 mM
Dex, or else of MM1S cells transfected for 72 h with synthetic mir-150-5p versus mock transfection, treated for 72 h with 1 nM Dex or a combination thereof
versus control samples.
doi:10.1371/journal.pone.0113842.g007
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Figure 8. Mir-150-5p transfection is associated with complex regulation of transcription factors, hormone receptors and chaperones. Illumina
BeadChip Gene Expression results of transcription factors (A), nuclear hormone receptors (B), and chaperones (C), are presented as bargraphs, reflecting
mean of gene expression fold change from three independent experiments of MM1S, treated for 72 h with 1 mM Dex versus control setup (UT), or else of
MM1S cells transfected for 72 h with synthetic mir-150-5p versus mock transfection.
doi:10.1371/journal.pone.0113842.g008
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5p induced gene expression changes are not sufficient to trigger GC induced cell
death and additional GC actions are required to kill the cells [15]. Next, we
evaluated whether ectopic mir-150-5p transfection may sensitize for GC induced
cell death. In this respect, mock and mir-150-5p transfected MM1S cells were
exposed to various doses of Dex for 72 h and cell survival was again evaluated by a
MTT-assay. From Fig. 10B, it can be observed that presence of mir-150-5p weakly
increases GC induced cell death at nanomolar (nM) concentrations, although no
significant effects could be discriminated at micromolar (mM) concentrations of
Dex treatment. Moreover, upon GC treatment of MM1S cells transfected with a
mir-150-5p specific antagomir, to reverse mir-150-5p effects, cell death could be
reversed at low GC doses. This prompted us to evaluate corresponding changes in
gene expression following GC treatment of MM1S cells transfected with mir-150-
5p antagomir. Although we could confirm weak GC specific upregulation of
mir150-5p and mild reduction of mir 150-5p levels upon GC treatment of MM1S
cells transfected with mir-150-5p specific antagomir (Fig. 10C), array approaches
seemed not sensitive enough to identify weak changes in gene repression or
activation in GC treated cells in presence or absence of the antagomir (Fig. 10D–E
and data not shown).
Figure 9. Mir-150-5p transfection is associated with complex regulation of chemokine, cell cycle, UPR/mTOR signaling. Illumina BeadChip Gene
Expression results of chemokine receptors or ligands (A), or regulators of cell cycle, unfolded protein stress (UPR/mTOR signaling) (B), are presented as
bargraphs, reflecting mean of gene expression fold change from three independent experiments of MM1S, treated for 72 h with 1 mM Dex versus control
setup (UT), or else of MM1S cells transfected for 72 h with synthetic mir-150-5p versus mock transfection.
doi:10.1371/journal.pone.0113842.g009
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Figure 10. Weak sensitisation of low dose GC therapy response by mir-150-5p mimetic transfection can be reversed by transfection of a mir-150-
5p-specific antagomir in MM1S cells. (A) MTT based quantification of MM1S cell survival, following 24, 48, or 72 h transfection with increasing doses of
synthetic mir-150-5p mimetic as compared to mock transfection control (B) MTT based quantification of MM1S cell survival, following 72 h treatment with
increasing doses of Dex, in combination with either mock transfection, else transfection with a synthetic mir-150-5p mimetic or mir-150-5p specific antagomir
(as indicated in figure). Data represented are relative cell survival levels (mean ¡ SEM) of three independent experiments. Means with ***, **, * are
significantly different (p,0.001,,0.01 or,0.05) from control setup as determined by two-way ANOVA (Bonferroni posttests). (C) Realtime quantitative PCR
(QPCR) quantification of mir-150-5p transcription levels following 72 h treatment with 1 nM Dex, either or not in combination with transfection of a mir-150-5p
specific antagomir. (D–E) Illumina BeadChip Gene Expression results of a subset of genes are presented as bargraphs, reflecting the mean fold change
from three independent experiments of MM1S cells treated for 72 h with 1 nM Dex vs. control setup, either or not in combination with transfection of a mir-
150-5p specific antagomir.
doi:10.1371/journal.pone.0113842.g010
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Discussion
Decreased proliferation and induction of cell death by apoptosis are two major
cellular events to reduce the growth of and to eliminate cancer cells. GCs are
known to induce a cell cycle arrest preceding apoptosis. Treating the cancerous
cells with higher doses of Dex can destabilize the glucocorticoid receptor (GR)
which ultimately results in GC resistance [38, 81, 82, 83]. The characterization of
miRNAs and their target mRNAs involved in regulation of the GC therapy
response and/or resistance is an area of intense research and relatively little is
known regarding GC specific miRNA regulatory networks. By combining
genome-wide transcriptome analysis and Ingenuity Pathway Analysis, we
envisioned to unravel the biological effects of GC responsive miRNAs and their
putative mRNA targets in MM GC therapy. We identified 30 GC inducible and 14
GC repressed microRNAs which might modulate multiple aspects of GC therapy
response in MM, including cell cycle, cell proliferation, DNA replication, gene
expression and cell death pathways. Similarly, a study of GC responsive
microRNAs in mucosal biopsies of eosinophilic esophagitis patients characterized
32 GC inducible and 4 GC repressed microRNAs, of which 7 GC inducible
microRNAs are in common with our list, irrespective of the cellular context [84].
Next, we selected mir-150-5p as the most interesting GC inducible microRNA for
further investigation because of its persistent upregulation by GC in MM1S cells
and its possible tumor suppressor functions in (malignant) haematopoiesis
[26, 54, 85, 86, 87]. According to IPA analysis, predicted mir-150-5p mRNA
targets were related to cell cycle and cell proliferation responses preceding
apoptosis. In line with IPA analysis, ectopic mir-150-5p expression in presence of
low GC concentrations was found to weakly sensitize for GC induced cell death,
whereas a mir-150-5p antagomir could reverse this effect. Remarkably, upon
ectopic transfection of mir-150-5p or GC treatment in MM1S cells, various
mRNAs were identified which respond similarly to increased mir-150-5p levels or
GC treatment (i.e. MYB, IL23A, SKP2, BUB1, SREBP1, FKBP5). This suggests that
mir-150-5p effects are strongly linked to GR function. Moreover, GR specific mir-
150-5p effects are completely lost in MM1R cells and mir-150-5p can not restore
GC sensitivity in MM1R cells lacking GR protein expression. Since mir-150-5p
overexpression did not substantially change GR expression levels, we believe the
GR like effects may be triggered via complex indirect regulation of GR interacting
transcription factors (MYB, C/EBP, JUN, FOS) or hormone receptors (NR3C2/
MR), GR chaperones (FKBP5, HSPA8, HSP90AB1), as well as various effectors of
unfolded protein stress (ATF4, DDIT3, DDIT4, TXNIP) and chemokine specific
signalling (CXCR3, CCL3, CCL5, CXCR4). Of special note, mir-150-5p selective
decrease in NR3C2 (MR) levels may result in reciprocal stimulation of GR actions
[58]. The GR dependent mir-150-5p effects also suggest that GR protein may
contribute in mir-150-5p specific post-transcriptional regulation. For example,
NR3C1 (GR) dependent post-transcriptional regulation of CCL2 and CCL7 but
not of CCL5 mRNA has been demonstrated upon RNA binding of GR to a GU
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rich motif at the 59UTR [88]. Alternatively, mir-150-5p may modulate GR/DNA
binding, in analogy to the long noncoding RNA Gas5 [24].
Altogether, we identified various novel and previously published GC inducible
microRNAs. Furthermore, multiple mir-150-5p responsive mRNAs are associated
with GC induced cell proliferation and cell death therapy response in multiple
myeloma. Functional cell survival studies in MM1S cells confirmed weak GC
therapy sensitizing effects of mir-150-5p overexpression at low GC dose, whereas
opposite effects could be observed in presence of a mir-150-5p specific antagomir.
However, although QPCR assays revealed reversal of Dex induced mir-150-5p
levels following antagomir transfection and attenuation of GC induced cell death,
subsequent microarray analysis failed to identify significant mir-150-5p specific
changes in GC regulated mRNA levels (Fig. 10D–E and data not shown). We
believe that the array study may lack sensitivity and statistical power to identify
significant mRNA changes when reversing a 2-fold time-dependent GC specific
induction of mir-150p levels by its antagomir, whereas a 30-fold overexpression in
mir150-5p levels following transfection may elicit more robust effects in gene
expression arrays. In a similar study, failure of antagomirs to reverse mir-92
specific gene expression changes despite reduced levels of mir-92 in presence of its
antagomir, was explained by possible redundancy in mir-92 regulated mRNA
networks [89]. Along the same line, since we identified various GC inducible
microRNAs related to the NR3C1 pathway, we can also not exclude redundant
mir-150-5p regulated mRNA networks involved in NR3C1 regulation. For
example, early GC inducible microRNAs, i.e. mir-26b, mir125-5p and mir184
could be responsible for subsequent increase of mir150-5p levels to fine tune GR
activity (Fig. 3C). Recent reports also show coupling of mir150-5p to mir124- and
mir155-networks [90, 91]. Alternatively, redundant mir-150-5p isomirs may
escape control of the antagomir [91]. Future research will be required to further
untangle specificity or redundancy of mir-150-5p-specific NR3C1 networks by
complementary transcriptomic and proteomic approaches. Finally, recent reports
demonstrating mir-150-5p secretion into microvesicles may allow development of
a diagnostic biomarker to follow GC therapy response or else, combination of low
GC doses with synthetic mir-150-5p vesicles may sensitize GC therapy responses
in lymphoid cancers [92, 93].
Supporting Information
Table S1. IPA prediction of microRNA targets based on correlation of
transcriptional changes of specific microRNAs (up/down) with changes in mRNA
levels (opposite direction down/up) and corresponding pathways in MM1S cells
treated for 72 h with Dex.
doi:10.1371/journal.pone.0113842.s001 (XLSX)
Table S2. Crosscomparison of 1203 Dex responsive target genes from MM1S cells
exposed for 72 h to 1 mM Dex (gene selection was done based on p-value ,0.05
and absolute fold change .1.5) and 3626 predicted hsa-mir-150-5p targets via the
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miRWalk database (prediction by at least 4 out of 10 available algorithms, i.e.
DIANAmT, miRanda, miRDB, miRWalk, RNAhybrid, PICTAR4, PICTAR5,
PITA, RNA22 and Targetscan) 196 common mRNA/gene targets were identified
in MM1S, which remain unaffected in MM1R cells.
doi:10.1371/journal.pone.0113842.s002 (XLSX)
Table S3. In silico prediction of microRNAs targeting the NR3C1 gene locus
versus the NR3C1 39 UTR.
doi:10.1371/journal.pone.0113842.s003 (XLSX)
Table S4. Detailed list of genes involved in cell cycle-proliferation, DNA repair
and cell death pathways which are similarly regulated in Dex treated and mir-150-
5p mimetic transfected MM1S cells, but which remain unaffected in MM1R cells
(values represent (fold change versus control cells)).
doi:10.1371/journal.pone.0113842.s004 (XLSX)
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